

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 January 2020 (30.01.2020)



(10) International Publication Number
WO 2020/023737 A1

(51) International Patent Classification:

A61K 31/712 (2006.01) C12N 15/113 (2010.01)

A61K 31/7125 (2006.01)

(21) International Application Number:

PCT/US2019/043424

(22) International Filing Date:

25 July 2019 (25.07.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/703,240 25 July 2018 (25.07.2018) US

(71) Applicant: **IONIS PHARMACEUTICALS, INC.**
[US/US]; 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(72) Inventors: **FREIER, Susan, M.**; 2855 Gazelle Ct., Carlsbad, CA 92010 (US). **SINGH, Priyam**; 13504 Ridley Rd, San Diego, CA 92129 (US). **RIGO, Frank**; 2855 Gazelle Ct., Carlsbad, CA 92010 (US). **JAFAR-NEJAD, Paymaan**; 2855 Gazelle Ct., Carlsbad, CA 92010 (US). **KORDASIEWICZ, Holly**; 2855 Gazelle Ct., Carlsbad, CA 92010 (US).

(74) Agent: **SCARR, Rebecca, B.** et al.; McNeill Baur PLLC, 125 Cambridge Park Dr, Suite 301, Cambridge, MA 02140 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOUNDS AND METHODS FOR REDUCING ATXN2 EXPRESSION

(57) Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN2 RNA in a cell or animal, and in certain instances reducing the amount of Ataxin-2 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include ataxia, neuropathy, and aggregate formation. Such neurodegenerative diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism.

WO 2020/023737 A1